Technical Analysis for TLSI - TriSalus Life Sciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 7.16 | -3.76% | -0.28 |
TLSI closed down 3.76 percent on Friday, May 31, 2024, on 67 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Resistance | Bearish | -3.76% |
| Alert | Time |
|---|---|
| Gap Up Closed | 2 days ago |
| Gap Up Partially Closed | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 3% | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Immunotherapy Immunotherapies Pancreatic Cancer Colorectal Cancer Hepatology Hepatocellular Carcinoma Uveal Melanoma Cholangiocarcinoma Intrahepatic Cholangiocarcinoma
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Immunotherapy Immunotherapies Pancreatic Cancer Colorectal Cancer Hepatology Hepatocellular Carcinoma Uveal Melanoma Cholangiocarcinoma Intrahepatic Cholangiocarcinoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.24 |
| 52 Week Low | 3.33 |
| Average Volume | 47,982 |
| 200-Day Moving Average | 7.55 |
| 50-Day Moving Average | 9.50 |
| 20-Day Moving Average | 9.22 |
| 10-Day Moving Average | 8.68 |
| Average True Range | 0.60 |
| RSI (14) | 27.54 |
| ADX | 30.56 |
| +DI | 7.61 |
| -DI | 38.12 |
| Chandelier Exit (Long, 3 ATRs) | 8.44 |
| Chandelier Exit (Short, 3 ATRs) | 8.60 |
| Upper Bollinger Bands | 11.25 |
| Lower Bollinger Band | 7.19 |
| Percent B (%b) | -0.01 |
| BandWidth | 44.05 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.26 |
| MACD Histogram | -0.2986 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.94 | ||||
| Resistance 3 (R3) | 8.01 | 7.81 | 7.81 | ||
| Resistance 2 (R2) | 7.81 | 7.61 | 7.78 | 7.77 | |
| Resistance 1 (R1) | 7.49 | 7.49 | 7.39 | 7.42 | 7.72 |
| Pivot Point | 7.29 | 7.29 | 7.24 | 7.26 | 7.29 |
| Support 1 (S1) | 6.97 | 7.09 | 6.87 | 6.90 | 6.60 |
| Support 2 (S2) | 6.77 | 6.97 | 6.74 | 6.55 | |
| Support 3 (S3) | 6.45 | 6.77 | 6.51 | ||
| Support 4 (S4) | 6.38 |
